January 24, 2013

Watson Pharmaceuticals has formally changed its name to Actavis and changed its New York Stock Exchange ticker symbol to ACT, the company said.

December 28, 2012

Watson Pharmaceuticals on Friday confirmed that Actavis, which was acquired by Watson in October, has filed an abbreviated new drug applications with the Food and Drug Administration seeking approval to market bortezomib, a generic version of Millennium Pharmaceuticals' Velcade.

December 20, 2012

Actavis has donated $200,000 worth of medicines to help people affected by Hurricane Sandy, a charity organization said Thursday.

November 29, 2012

Watson Pharmaceuticals is changing its name to Actavis following its acquisition of the Swiss drug maker, Watson said.

November 19, 2012

The year 2012 is coming to an end, and it's been a big year for generic drugs. It's the year that the most lucrative drug of all time became commoditized. It's the year that Watson bought Actavis for $5.6 billion. And it's the year the FDA released draft guidance for biosimilars regulations. All of these events speak to some of the most important trends in the world of generics — trends that are often interrelated.

November 15, 2012

Initial shipment of a generic appetite suppressant has started, the drug's manufacturer said Thursday.

November 5, 2012

In what its president and CEO called a “significant milestone,” Watson Pharmaceuticals announced last month that the U.S. Federal Trade Commission and European Commission had approved its acquisition of Swiss generic drug maker Actavis.

November 1, 2012

Watson Pharmaceuticals is changing its name to Actavis following its acquisition of the Swiss drug maker, Watson said.

October 22, 2012

Watson Pharmaceuticals and Actavis will have to divest rights to almost two dozen drugs as a condition for U.S. regulatory approval of their $5.6 billion merger announced earlier this year, according to regulatory documents.

October 16, 2012

The Federal Trade Commission has voted to approve Watson Pharmaceutical's acquisition of Switzerland-based generic drug maker Actavis.

October 16, 2012

Par Pharmaceutical Cos. has entered into agreements with Watson Pharmaceuticals and Actavis to purchase five generic products currently marketed in the United States by Watson or Actavis, eight abbreviated new drug applications currently awaiting regulatory approval, and a generic product in late-stage development.

October 10, 2012

The Food and Drug Administration has approved a generic drug for treating blood pressure and chest pain.

October 8, 2012

European regulators have approved U.S. drug maker Watson's acquisition of Switzerland-based Actavis, Watson said.

September 18, 2012

Over the last few years of DSN’s coverage of the impending patent cliff and how it would affect the generic drug industry, IMS Health VP industry relations Doug Long predicted that the gradual commoditization of primary care drugs — long the lifeblood of generic drug makers — would lead to consolidation of the industry.


July 17, 2012

Watson Pharmaceuticals confirmed it received a request for additional information from the Federal Trade Commission in connection with the drug maker's pending acquisition of Actavis Group.

July 5, 2012

Actavis has received a preliminary approval for a generic drug for treating high blood pressure, the drug maker said Thursday.

June 25, 2012

The Food and Drug Administration has approved a generic drug for attention deficit hyperactivity disorder made by Actavis, the drug maker said Monday.

May 31, 2012

Actavis has launched a generic drug for high blood pressure and chest pain, the company said.

May 18, 2012

The Food and Drug Administration has approved a treatment for Parkinson's disease made by Actavis, the drug maker said Friday.

May 16, 2012

Watson has announced its intention to acquire Actavis, the company said. Following news reports that the U.S.-based generic drug maker would acquire Switzerland-based Actavis, Watson announced that it would buy the latter for $5.6 billion.

May 10, 2012

Generic drug maker Watson Pharmaceuticals has formed a special office to handle its pending acquisition of Actavis, the company said.

April 26, 2012

Watson has announced its intention to acquire Actavis, the company said.

April 24, 2012

Watson Pharmaceuticals is buying Actavis Group for $5.9 billion, according to published reports.

March 21, 2012

Watson Pharmaceuticals is looking to acquire Actavis, according to published reports.